Top Page
Clene
(NASDAQ:CLNN)
Clene (CLNN) vs. SPDR S&P 500 ETF (SPY)
Clene Business Overview & Revenue Model
Clene Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 286.00K | 342.00K | 654.00K | 473.00K | 723.00K | 206.00K |
| Gross Profit | 230.00K | 272.00K | 533.00K | 447.00K | 434.00K | 141.00K |
| EBITDA | -29.64M | -33.69M | -43.24M | -25.21M | -8.22M | -16.92M |
| Net Income | -29.70M | -39.40M | -49.50M | -15.28M | -9.74M | -19.28M |
Balance Sheet | ||||||
| Total Assets | 22.13M | 27.34M | 52.34M | 44.49M | 63.06M | 68.24M |
| Cash, Cash Equivalents and Short-Term Investments | 7.29M | 12.15M | 35.00M | 23.32M | 50.29M | 59.27M |
| Total Debt | 20.85M | 20.84M | 32.16M | 31.82M | 24.04M | 4.32M |
| Total Liabilities | 30.68M | 36.19M | 38.95M | 41.26M | 50.47M | 67.90M |
| Stockholders Equity | -8.55M | -8.86M | 13.39M | 3.24M | 12.60M | 341.00K |
Cash Flow | ||||||
| Free Cash Flow | -17.64M | -21.34M | -30.50M | -44.19M | -35.96M | -19.32M |
| Operating Cash Flow | -17.64M | -21.33M | -30.17M | -39.01M | -34.62M | -18.93M |
| Investing Cash Flow | -3.00K | 6.32M | -1.50M | -10.16M | -1.33M | -387.00K |
| Financing Cash Flow | 3.27M | -1.53M | 42.16M | 17.25M | 27.11M | 69.53M |
Clene Technical Analysis
Clene Risk Analysis
Clene Peers Comparison
Clene Corporate Events
Clene Inc., a company in the biotechnology sector, has entered into an equity distribution agreement with Canaccord Genuity LLC to sell up to $25 million in common stock. As of October 17, 2025, Clene has filed a prospectus supplement to offer an additional $18.88 million in shares, following previous sales totaling approximately $6.12 million, potentially impacting its financial strategy and market presence.
The most recent analyst rating on (CLNN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
On September 25, 2025, Clene announced new clinical data at the ECTRIMS 2025 meeting, highlighting that their product CNM-Au8 improves brain energy metabolism in multiple sclerosis patients. This announcement could enhance Clene’s positioning in the pharmaceutical industry, potentially impacting stakeholders by showcasing the effectiveness of their treatment in a significant medical condition.
The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
On April 28, 2025, Clene Inc. entered into an equity distribution agreement with Canaccord Genuity LLC to offer and sell shares of its common stock, aiming to raise up to $25,000,000. By September 5, 2025, the company had already sold shares worth approximately $3,706,213 and filed a prospectus supplement for an additional $6,280,000 of shares, reflecting its ongoing efforts to bolster financial resources.
The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
Clene Inc. is a clinical-stage pharmaceutical company focused on developing novel nanotechnology therapeutics primarily for neurological disorders such as ALS, MS, and Parkinson’s disease. In its latest earnings report for the quarter ended June 30, 2025, Clene Inc. reported a net loss of $7.4 million, a slight improvement from the $6.8 million loss in the same quarter last year. The company’s revenue remains minimal, with total revenue of $27,000 for the quarter, reflecting a decline from the previous year’s $91,000. The company’s operating expenses have decreased, with research and development expenses dropping significantly, contributing to a reduced loss from operations. Clene Inc. continues to face financial challenges with a substantial accumulated deficit and limited cash reserves, raising concerns about its ability to continue as a going concern. The company is actively seeking additional funding through various means to support its operations and advance its drug development programs. Looking ahead, Clene Inc.’s management remains focused on securing the necessary resources to continue its research and development efforts and achieve its strategic goals in the pharmaceutical industry.
On August 13, 2025, Clene Inc. announced amendments to its December 2024 senior secured convertible promissory notes, extending the maturity date to February 13, 2027, and postponing the commencement of monthly principal repayments to September 13, 2026. Additionally, the company entered into a new note purchase agreement with AE Capital Limited and others, issuing $1.5 million in senior secured convertible promissory notes. These financial maneuvers aim to provide Clene with a cash runway into the first quarter of 2026, supporting its ongoing clinical programs. Clene also reported its second quarter 2025 financial results, highlighting a net loss of $7.4 million and cash reserves of $7.3 million as of June 30, 2025. The company is advancing its CNM-Au8 programs for ALS and MS, with significant FDA meetings scheduled for the third quarter of 2025, aiming for a new drug application submission for ALS by the end of 2025.
The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.